P1‐362: EFFICACY AND SAFETY OF MONTHLY SUBCUTANEOUS BAPINEUZUMAB | Zendy

Novak Gerald | Zendy; Di Jianing | Zendy; Brashear Robert H. | Zendy; Werth John | Zendy; Booth Kevin | Zendy; Margolin Richard | Zendy; Lu Ming | Zendy; Liu Enchi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

P1‐362: EFFICACY AND SAFETY OF MONTHLY SUBCUTANEOUS BAPINEUZUMAB

Author(s) -

Novak Gerald,

Di Jianing,

Brashear Robert H.,

Werth John,

Booth Kevin,

Margolin Richard,

Lu Ming,

Liu Enchi

Publication year - 2014

Publication title -

alzheimer's and dementia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.713

H-Index - 118

eISSN - 1552-5279

pISSN - 1552-5260

DOI - 10.1016/j.jalz.2014.05.604

Subject(s) - medicine , placebo , asymptomatic , regimen , incidence (geometry) , gastroenterology , pathology , physics , alternative medicine , optics

baseline correlated strongly with the AUC of Ab-IgG titers over 78 weeks. Using the CAD106 study only, SUVR decreased over time in SSRs (LS mean percentage change, 1.17%) but not in controls (2.29%), resulting in a 3.46% (31.04%, 24.12%) difference between groups. The LS mean percentage change was 1.82% in SSRs vs 11.13% for enriched controls (12.96%, 26.58%, 0.67%) difference between groups). Conclusions: PET 18 F-florbetapir data are consistent with a decrease over time in brain amyloid load in patients developing a strong serological response to CAD106 treatment. This is the first indication that CAD106-induced antibodies bind amyloid in the human brain.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research